Didanosine-d2
(Synonyms: 去羟肌苷 d2) 目录号 : GC49022An internal standard for the quantification of didanosine
Cas No.:69655-05-6
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Didanosine-d2 is intended for use as an internal standard for the quantification of didanosine by GC- or LC-MS. Didanosine is an antiviral nucleoside analog and an inhibitor of reverse transcriptase.1 It undergoes cellular amination and phosphorylation to its active triphosphate form, 2’,3’-dideoxyadenosine 5’-triphosphate . Didanosine inhibits human T cell leukemia virus type 1 (HTLV-1) reverse transcriptase activity (IC50 = 30 nM).2 It inhibits the replication of HIV-1 clinical isolates containing various mutations in the gene encoding reverse transcriptase, pol, in isolated human peripheral blood mononuclear cells (PBMCs; IC50s = 0.3-11.1 μM).3 Didanosine inhibits proliferation and differentiation of primary human skeletal muscle cells (IC50s = 1 and 0.1 mM, respectively), as well as decreases the activities of mitochondrial complex IV, also known as cytochrome c oxidase, and mitochondrial complex II, also known as succinate dehydrogenase, in the same cells when used at a concentration of 1 mM.4 In vivo, didanosine protects mice from HIV infection (EC50 = 13.7 mg/kg).5 Formulations containing didanosine have been used in the treatment of HIV-1 infections.
1.Perry, C.M., and Noble, S.Didanosine: An updated review of its use in HIV infectionDrugs58(6)1099-1135(1999) 2.Anantharaman, V., and Moen, L.K.Effects of nucleoside analogs on native and site-directed mutants of HTLV type 1 reverse transcriptaseBioorg. Chem.28(5)293-305(2000) 3.Eron, J.J., Chow, Y.-K., Caliendo, A.M., et al.pol Mutations conferring zidovudine and didanosine resistance with different effects in vitro yield multiply resistant human immunodeficiency virus type 1 isolates in vivoAntimicrob. Agents Chemother.37(7)1480-1487(1993) 4.Benbrik, E., Chariot, P., Bonavaud, S., et al.Cellular and mitochondrial toxicity of zidovudine (AZT), didanosine (ddI) and zalcitabine (ddC) on cultured human muscle cellsJ. Neurol. Sci.149(1)19-25(1997) 5.Kaneshima, H., Shih, C.C., Namikawa, R., et al.Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouseProc. Natl. Acad. Sci. USA88(10)4523-4527(1991)
Cas No. | 69655-05-6 | SDF | |
别名 | 去羟肌苷 d2 | ||
Canonical SMILES | OC[C@@H]1CC[C@H](N2C([2H])N=C3C2N=C([2H])NC3=O)O1 | ||
分子式 | C10H12D2N4O3 | 分子量 | 240.3 |
溶解度 | DMSO : 62.5 mg/mL (264.57 mM; Need ultrasonic) | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.1615 mL | 20.8073 mL | 41.6146 mL |
5 mM | 0.8323 mL | 4.1615 mL | 8.3229 mL |
10 mM | 0.4161 mL | 2.0807 mL | 4.1615 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。